Corporate Banner
Satellite Banner
Technology Networks Header
Sunday, November 23, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
MDxI Launches LabFile Data Resource
Friday, July 25, 2014
New standard for defining and targeting US clinical laboratory universe.

New Paraffin Section Flotation Bath from Electrothermal
Thursday, July 24, 2014
New bath updates Electrothermal’s extensive histology range.

EKF Diagnostics’ Growing Product Portfolio Highlighted at AACC 2014
Thursday, July 24, 2014
From early detection of ketosis to cancer mutation testing in whole blood.

Seegene to Unveil at AACC 2014 the Innovative Real-Time PCR Technology
Thursday, July 24, 2014
MuDT™ technology doubles the channel availability of any real-time PCR instrument.

WHEATON® Highlights Products at AACC 2014
Thursday, July 24, 2014
The products to be featured at the meeting offer unique solutions for the clinical market.

New Data Using EKF PointMan™ Technology
Tuesday, July 22, 2014
New data suggest the possibility of a simple blood test for cancers.

The Hiden EQP Plasma Diagnostic with On-board MCA
Tuesday, July 22, 2014
A pure research tool specifically derived and enhanced for the plasma researcher.

ACD’s RNAscope® In Situ Hybridization Technology Gains Significant Traction
Wednesday, July 16, 2014
Highly sensitive and easy-to-use technology validated in over 100 papers in three years.

Tecan Launches New Options for Cavro® Omni Robot
Wednesday, July 16, 2014
Cavro Omni Robot Version 4.0 launched at the AACC’s 2014 Clinical Lab Expo.

<< 2 3 4 5 6 7 8 >>
Showing Results 41 - 50 of 483
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv